Search research articles
Contact Us
Filters
Showing results (151-160 of 201) with videos related to
Page
of 21
Sort By:
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Medicinal Chemistry
|
January 26, 2012
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors
Rongshi Li, Mathew P Martin, Yan Liu, et al.
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Cell Chemical Biology
|
July 30, 2021
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Vinayak Palve, Claire E Knezevic, Daniel S Bejan, et al.
Molecular & Cellular Proteomics : MCP
|
July 31, 2008
Proteomic contributions to personalized cancer care
John M Koomen, Eric B Haura, Gerold Bepler, et al.
Science Signaling
|
February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosome
Maria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
The Journal of Clinical Investigation
|
May 4, 2016
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Zirong Chen, Jian-Liang Li, Shuibin Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E Gray, Andreas Saltos, Tawee Tanvetyanon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2014
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer
Takeshi Yoshida, Guolin Zhang, Matthew A Smith, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 201) with videos related to
Sort By:
Page
of 21
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Medicinal Chemistry
|
January 26, 2012
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors
Rongshi Li, Mathew P Martin, Yan Liu, et al.
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Cell Chemical Biology
|
July 30, 2021
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
Vinayak Palve, Claire E Knezevic, Daniel S Bejan, et al.
Molecular & Cellular Proteomics : MCP
|
July 31, 2008
Proteomic contributions to personalized cancer care
John M Koomen, Eric B Haura, Gerold Bepler, et al.
Science Signaling
|
February 14, 2019
An immunoproteomic approach to characterize the CAR interactome and signalosome
Maria C Ramello, Ismahène Benzaïd, Brent M Kuenzi, et al.
The Journal of Clinical Investigation
|
May 4, 2016
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Zirong Chen, Jian-Liang Li, Shuibin Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E Gray, Andreas Saltos, Tawee Tanvetyanon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2014
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer
Takeshi Yoshida, Guolin Zhang, Matthew A Smith, et al.
Page
of 21